$4.70
0.00% day before yesterday
Nasdaq, Aug 30, 02:00 am CET
ISIN
US75629V1044
Symbol
RXRX

Recursion Pharmaceuticals Stock price

$4.70
-1.25 21.01% 1M
-2.81 37.42% 6M
-2.06 30.47% YTD
-2.71 36.57% 1Y
-5.50 53.92% 3Y
-26.60 84.98% 5Y
-26.60 84.98% 10Y
-26.60 84.98% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
-0.17 3.39%
ISIN
US75629V1044
Symbol
RXRX
Industry

Key metrics

Basic
Market capitalization
$2.0b
Enterprise Value
$1.5b
Net debt
positive
Cash
$525.1m
Shares outstanding
432.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
31.6 | 28.0
EV/Sales
23.9 | 21.1
EV/FCF
negative
P/B
2.2
Financial Health
Equity Ratio
71.4%
Return on Equity
-44.8%
ROCE
-57.1%
ROIC
-90.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$64.6m | $73.0m
EBITDA
$-586.4m | $-535.8m
EBIT
$-649.7m | $-577.1m
Net Income
$-649.1m | $-694.8m
Free Cash Flow
$-393.9m
Growth (TTM | estimate)
Revenue
30.2% | 24.1%
EBITDA
-53.8% | -16.4%
EBIT
-64.3% | -20.5%
Net Income
-73.1% | -49.9%
Free Cash Flow
-15.1%
Margin (TTM | estimate)
Gross
-3.5%
EBITDA
-907.8% | -733.8%
EBIT
-1,005.8%
Net
-1,004.9% | -951.6%
Free Cash Flow
-609.8%
More
EPS
$-1.6
FCF per Share
$-0.9
Short interest
30.2%
Employees
800
Rev per Employee
$70.0k
Show more

Is Recursion Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Recursion Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Recursion Pharmaceuticals forecast:

7x Buy
50%
7x Hold
50%

Analyst Opinions

14 Analysts have issued a Recursion Pharmaceuticals forecast:

Buy
50%
Hold
50%

Financial data from Recursion Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
65 65
30% 30%
100%
- Direct Costs 67 67
63% 63%
103%
-2.27 -2.27
127% 127%
-4%
- Selling and Administrative Expenses 216 216
69% 69%
335%
- Research and Development Expense 420 420
61% 61%
650%
-586 -586
54% 54%
-908%
- Depreciation and Amortization 63 63
349% 349%
98%
EBIT (Operating Income) EBIT -650 -650
64% 64%
-1,006%
Net Profit -649 -649
73% 73%
-1,005%

In millions USD.

Don't miss a Thing! We will send you all news about Recursion Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Recursion Pharmaceuticals Stock News

Neutral
The Motley Fool
3 days ago
Prosper Junior Bakiny has positions in Nvidia and Recursion Pharmaceuticals. The Motley Fool has positions in and recommends Nvidia.
Neutral
GlobeNewsWire
5 days ago
Salt Lake City, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: Citi 2025 BioPharma Back to School Conference — Wednesday, September 3, 2025 Morgan Stanley 23rd Annual Global Healthcare Conference — Monday, September ...
Neutral
The Motley Fool
7 days ago
Many investors seek to capitalize on the rapidly growing artificial intelligence (AI) industry. One way to do that is to buy shares of the leading companies in the field, such as Nvidia.
More Recursion Pharmaceuticals News

Company Profile

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Chistopher Gibson
Employees 800
Founded 2013
Website www.recursion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today